Compare RENX & BMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RENX | BMRA |
|---|---|---|
| Founded | 2021 | 1971 |
| Country | United States | United States |
| Employees | N/A | 54 |
| Industry | | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7M | 5.0M |
| IPO Year | 2023 | 1995 |
| Metric | RENX | BMRA |
|---|---|---|
| Price | $1.95 | $1.59 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 50.2K | 4.8K |
| Earning Date | 05-22-2026 | 04-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,220,449.00 | $5,311,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 3860.67 | N/A |
| 52 Week Low | $0.09 | $1.45 |
| 52 Week High | $3.48 | $3.51 |
| Indicator | RENX | BMRA |
|---|---|---|
| Relative Strength Index (RSI) | 48.37 | 51.10 |
| Support Level | $1.66 | N/A |
| Resistance Level | $2.14 | $1.71 |
| Average True Range (ATR) | 0.14 | 0.05 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 42.13 | 78.22 |
RenX Enterprises Corp is engaged in real property development using purpose-built, prefabricated modules constructed from both wood and steel. The Company's operations mainly focused on the acquisition, entitlement, and development of residential properties in high-growth markets across the United States. These efforts included the direct acquisition of land, strategic investments in real estate entities, and joint venture partnerships targeting green, single-family, and multifamily housing projects. The company operates in four segments: real estate development, technology, compost sales, and logistics. The company generates from the compost sales.
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which focus on the development, manufacture, marketing, and sale of diagnostic products. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.